CA-TULA-TECHNOLOGY
10.11.2021 10:02:08 CET | Business Wire | Press release
As world leaders gather in Glasgow for the 26th United Nations Climate Change Conference of the Parties (COP26), there is once again a push for strategies to reach net zero by 2050. With the transportation sector currently the fastest growing contributor to climate change and now accounting for almost a quarter of emissions, Tula Technology, Inc., a leader in propulsion efficiency, has accelerated the pace of innovation to reduce the environmental impact of passenger and commercial vehicles through its Dynamic Skip Fire (DSF®) and Dynamic Motor Drive (DMD™) technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005156/en/
“To reach net zero, OEMs are faced with meeting increasingly stringent emissions reductions standards,” said R. Scott Bailey, president and CEO of Tula Technology. “Tula has developed technologies that make it possible to achieve these mandates in a cost-effective manner. Whether we’re working with partners to reduce emissions in internal combustion engines or offering solutions to make electric vehicles more efficient, our team is committed to improving propulsion efficiency for a cleaner environment.”
The Tula Track Record of Innovation
- Using patented algorithms, DSF® chooses to skip or fire individual cylinders dynamically to meet an engine’s torque demands, enabling near-peak engine efficiency for a cleaner-burning, more fuel-efficient vehicle.
- DMD™ mitigates efficiency losses in electric motors while significantly reducing reliance on rare-earth materials. DMD’s application to electric vehicles (EVs) has the potential to increase range while using less energy. DMD is a cost-effective, software-driven solution. Without the need for rare earth materials , potential supply chain challenges and escalating costs can be avoided.
- A recent study of Tula’s DSF in a Class 8 truck powered by a Cummins X15 HD engine showed a 74 percent reduction in nitrogen oxides (NOX ) and a 5 percent reduction in carbon dioxide (CO2 ) . To demonstrate DSF in action, Tula recently released a “virtual test drive” video.
- FEV, an international engineering partner to the auto industry, joined Tula to evaluate Tula’s DSF for mild hybrid diesel vehicles and found an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of about $235 (€200) per vehicle. For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.
- Tula and Jacobs Vehicle Systems signed an agreement and are working together to integrate DSF and Jacobs Cylinder Deactivation technology . Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s DSF achieve greater emission reductions when combined.
- Tula is partnering with Chinese vehicle equipment manufacturer E-Quality Tec, Inc. to embed DSF into E-Quality’s controller . Rapidly deploying fully integrated technology will enable medium and heavy-duty diesel vehicle manufacturers in China to aggressively target simultaneous reductions in both CO2 and NOX for CN Stage VI, China’s emission standard for heavy-duty vehicles.
- More than 1.5 million General Motors passenger vehicles are on the road in the U.S. utilizing DSF, each one saving roughly one ton of CO2 emissions each year, using the same cost-effective technology being deployed in commercial diesel and hybrid vehicles.
- Tula’s talented team members are on the cutting edge of automotive engineering, and recently were awarded their 200th global patent and have 378 patents issued or pending .
Tula is driven to improve efficiency across all manner of transportation and reduce emissions without sacrificing performance or comfort. We support immediate action on climate and clean air regulations to promote a sustainable future powered by innovation.
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
